Telix Pharmaceuticals Limited (TLX.AX)
AUD 26.32
(-0.15%)
AUD 26.32
(-0.15%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 269.26 Million AUD | 162.65% |
| 2022 | 102.51 Million AUD | 99.13% |
| 2021 | 51.48 Million AUD | 59.01% |
| 2020 | 32.37 Million AUD | 14.08% |
| 2019 | 28.38 Million AUD | 1.91% |
| 2018 | 27.84 Million AUD | 326.93% |
| 2017 | 6.52 Million AUD | 21643.75% |
| 2016 | 30 Thousand AUD | -74.14% |
| 2015 | 116 Thousand AUD | 0.0% |
| 2000 | -994 Thousand AUD | -71.97% |
| 1999 | -578 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 110.12 Million AUD | 0.0% |
| 2023 Q2 | 59.37 Million AUD | 0.0% |
| 2023 FY | 269.26 Million AUD | 162.65% |
| 2023 Q4 | 203.9 Million AUD | 0.0% |
| 2022 Q4 | 54.59 Million AUD | 0.0% |
| 2022 FY | 102.51 Million AUD | 99.13% |
| 2022 Q2 | 47.92 Million AUD | 0.0% |
| 2021 Q4 | 31.05 Million AUD | 0.0% |
| 2021 FY | 51.48 Million AUD | 59.01% |
| 2021 Q2 | 20.42 Million AUD | 0.0% |
| 2020 Q2 | 11.48 Million AUD | 0.0% |
| 2020 FY | 32.37 Million AUD | 14.08% |
| 2020 Q4 | 20.89 Million AUD | 0.0% |
| 2019 FY | 28.38 Million AUD | 1.91% |
| 2019 Q2 | 10.01 Million AUD | 0.0% |
| 2019 Q4 | 18.36 Million AUD | 0.0% |
| 2018 FY | 27.84 Million AUD | 326.93% |
| 2018 Q2 | 5.34 Million AUD | 29441.65% |
| 2018 Q1 | 18.08 Thousand AUD | -99.62% |
| 2018 Q4 | 10.88 Million AUD | 0.0% |
| 2017 Q4 | 4.81 Million AUD | 0.0% |
| 2017 Q2 | 1.59 Million AUD | 630.81% |
| 2017 FY | 6.52 Million AUD | 21643.75% |
| 2017 Q1 | 217.75 Thousand AUD | 0.0% |
| 2016 Q4 | 217.75 Thousand AUD | 0.0% |
| 2016 FY | 30 Thousand AUD | -74.14% |
| 2015 FY | 116 Thousand AUD | 0.0% |
| 2000 Q3 | -248.5 Thousand AUD | 0.0% |
| 2000 Q2 | -248.5 Thousand AUD | 0.0% |
| 2000 Q1 | -248.5 Thousand AUD | 0.0% |
| 2000 FY | -994 Thousand AUD | -71.97% |
| 1999 Q1 | -144.5 Thousand AUD | 0.0% |
| 1999 FY | -578 Thousand AUD | 0.0% |
| 1999 Q4 | -248.5 Thousand AUD | -71.97% |
| 1999 Q3 | -144.5 Thousand AUD | 0.0% |
| 1999 Q2 | -144.5 Thousand AUD | 0.0% |
| 1998 Q4 | -144.5 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -3877.63% |
| Acrux Limited | 8.55 Million AUD | -3049.31% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -44641.949% |
| BTC Health Limited | -1.03 Million AUD | 26017.702% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -1262.177% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | -378.208% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | -760.356% |
| Biome Australia Limited | 7.91 Million AUD | -3303.596% |
| Hexima Limited | 1 Million AUD | -26593.036% |
| Immutep Limited | 42.87 Million AUD | -528.023% |
| Memphasys Limited | 3.67 Million AUD | -7220.229% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | -723.519% |
| Noxopharm Limited | 7 Million AUD | -3746.552% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -2370.606% |
| Race Oncology Limited | 14.77 Million AUD | -1723.002% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -89886.9% |
| Starpharma Holdings Limited | 22.81 Million AUD | -1080.163% |
| Tissue Repair Ltd | 6.66 Million AUD | -3938.903% |
| Biotron Limited | 5.11 Million AUD | -5168.697% |
| Alterity Therapeutics Limited | 23.4 Million AUD | -1050.381% |
| CSL Limited | 7.56 Billion AUD | 96.439% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | -580.404% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -37813.201% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -9652.432% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -4426.61% |
| Patrys Limited | 4.93 Million AUD | -5358.117% |
| Orthocell Limited | 15.36 Million AUD | -1651.946% |
| Imugene Limited | 135.09 Million AUD | -99.322% |
| PYC Therapeutics Limited | 60.91 Million AUD | -342.024% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -30081.933% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -2320.681% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -2396.606% |
| Nanollose Limited | 12.5 Thousand AUD | -2153855.684% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -7947.681% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -13601.563% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -3091.973% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -6427.097% |
| Nyrada Inc. | 4.55 Million AUD | -5811.22% |
| Dimerix Limited | 25.64 Million AUD | -950.046% |
| PharmAust Limited | 6.65 Million AUD | -3944.862% |
| AnteoTech Limited | 12.18 Million AUD | -2109.453% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | -313.599% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -1141.746% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -5823.931% |
| Actinogen Medical Limited | 22.77 Million AUD | -1082.522% |
| Immuron Limited | 9.13 Million AUD | -2846.69% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -3156.275% |